The therapeutic potential of dopamine modulators on the cardiovascular and renal systems

Bibliography

• BARILI P, SABBATINI M, SOARES-DA-SILVA P, AMENTA F: Dopamine D2-like receptors in the rat kidney: Effect of denervation. Ear: Pharmacol (1997) 334:233–240.
   PubMed Web of Science ®Google Scholar
• MÜHLBAUER B, HARTENBURG E, OSSWALD H: Renal response to amino acid infusion in rats: effect of dopamine receptor antagonists and benserazide. Naunyn Schnnedebergs Arch. Pharmacol. (1994) 349:244–249.
   PubMed Web of Science ®Google Scholar
• LUIPPOLD G, MÜHLBAUER B: Dopamine D2 receptors mediate glomerular hyperfiltration due to amino acids. Pharmacol Exp. The]: (1998) 286:1248–1252.
   Google Scholar
• LUIPPOLD G, SCHNEIDER S, STEFANESCU A, BENOHR P, MOHLBAUER B: Dopamine D2-loke receptors and amino acid-induced glomerular hyperfiltration in humans. Br. I Clin. Pharmacol (2001) 51:415–421.
   PubMed Web of Science ®Google Scholar
• LUIPPOLD G, SCHNEIDER S, VALLON V, OSSWALD H, MÜHLBAUER B: Postglomerular vasoconstriction induced by dopamine D3 receptor activation in anesthetized rats. Am. I Physic] Renal Physiol (2000) 278:F570–F575.
   PubMed Web of Science ®Google Scholar
• APERIA AC: Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Ann. Rev. Physic] (2000) 62:621–647.
   PubMed Web of Science ®Google Scholar
• •Good review of intrarenal dopamine.
   Google Scholar
• CHENG HF, BECKER BN, HARRIS RC: Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J. Clin. Invest. (1996) 97:2745–2752.
   PubMed Web of Science ®Google Scholar
• SUN D, WILBORN TW, SCHAFER JA: Dopamine D4 receptor isoform mRNA and protein are expressed in the rat cortical collecting duct. Am. J. Physic] (1998) 275:F742–F751.
   Web of Science ®Google Scholar
• CAREY RM: Renal dopamine system. Hypertension (2001) 38:297–302.
   PubMed Web of Science ®Google Scholar
• •Good review of renal dopamine.
   Google Scholar
• WANG ZQ, FELDER RA, CAREY PM: Selective inhibition of the renal dopamine subtype DiA receptor induces antinatriuresis in conscious rats. Hypertension (1999) 33:504–510.
   PubMed Web of Science ®Google Scholar
• CHIBALIN AV, KATZ Al, BERGGREN P-O, BERTORELLO AM: Receptor-mediated inhibition of renal Na+-K4LATP-ase is associated with endocytosis of its a- and 13-subunits. Am. J. Physic] (1997) 273:C1458–C1465.
   Web of Science ®Google Scholar
• DE TOLEDO FG, BEERS KW, BERNDT TJ et al.: Opposite paracrine effects of 5-HT and dopamine on Na+-Pi cotransport in opossum kidney cells. Kidney Int. (1997) 52:152–156.
   PubMed Web of Science ®Google Scholar
• LEDERER ED, SOHI SS, MCLEISH KR: Dopamine regulates phosphate uptake by opossum kidney cells through multiple counter-regulatory receptors. Am. Soc. Nephrol (1998) 9:975–985.
   PubMed Web of Science ®Google Scholar
• FUIANO G, SUND S, MAZZA G et al: Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int. (2001) 59:1052–1058.
   PubMed Web of Science ®Google Scholar
• SOARES-DA-SILVA P, FERNANDES MH: A study on the renal synthesis of dopamine in aged rats. Acta Physiol Scand. (1991) 143:287–293.
   PubMedGoogle Scholar
• ARMANDO I, NOWICKI S, AGUIRRE J, BARONTINI M: A decreased tubular uptake of dopa results in defective renal dopamine production in aged rats. Am. Physiol (1995) 268:F1087–F1092.
   PubMed Web of Science ®Google Scholar
• KANSRA V, HUSSAIN T, LOKHANDWALA MF: Alterations in dopamine DAi receptor and G proteins in renal proximal tubules of old rats. Am. J. Physiol (1997) 273:F53–F59.
   PubMed Web of Science ®Google Scholar
• NISHI A, EKLOF AC, BERTORELLO AM, APERIA A: Dopamine regulation of renal Na±,KLATPase activity is lacking in Dahl salt-sensitive rats. Hypertension (1993) 21:767–771.
   PubMed Web of Science ®Google Scholar
• LUIPPOLD G, ZIMMERMANN C, MAT M et al: Dopamine d3 receptors and salt-dependent hypertension. I Am. Soc. Nephrol (2001) 12:2272–2279.
   PubMed Web of Science ®Google Scholar
• PESTANA M, JARDIM H, SERRAO P, SOARES-DA-SILVA P, GUERRA L: Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease. Kidney Blood Press. Res. (1998) 21:59–65.
   PubMed Web of Science ®Google Scholar
• ALBRECHT FE, DRAGO J, FELDER RA et al.: Role of the D iA dopamine receptor in the pathogenesis of genetic hypertension. Clin. Invest. (1996) 97:2283–2288.
   Google Scholar
• MATSUMOTO T, OZONO R, SASAKI N et al.: Type la dopamine receptor expression in the heart is not altered in spontaneously hypertensive rats. Am. J. Hypertens. (2000) 13:673–677.
   PubMed Web of Science ®Google Scholar
• LI XX, BEK M, ASICO LD et al: Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension (2001) 38:303–308.
   PubMed Web of Science ®Google Scholar
• ASICO LD, LADINES C, FUCHS S et al:Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J. Gin. Invest. (1998) 102:493–498.
   PubMed Web of Science ®Google Scholar
• DE VRIES PA, NAVIS G, DE JONG PE,DE ZEEUW D, KLIPPEL CA: Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. Cardiovasc. Pharmacol (1999) 34:191–198.
   PubMed Web of Science ®Google Scholar
• KINOSHITA S, SIDHU A, FELDER RA: Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat. J. Clin. Invest. (1989) 84:1849–1856.
   PubMed Web of Science ®Google Scholar
• HUSSAIN T, LOKHANDWALA MF: Renal dopamine DAi receptor coupling with Cr(s) and G(qiii) proteins in spontaneously hypertensive rats. Am. J. Physiol. (1997) 273:F339–F346.
   Google Scholar
• BARILI P, FRINGUELLI C, BALDONE E et al.: Dopamine D2-like receptors in the kidney of spontaneously hypertensive rats: a radioligand binding assay and light microscopic autoradiography study. J. Auton. Pharmacol. (1998) 18:89–97.
   PubMedGoogle Scholar
• GILL JR Jr, GULLNER G, LAKE CR, LAKATUA DJ, LAN G: Plasma and urinary catecholamines in salt-sensitive idiopathic hypertension. Hypertension (1988) 11:312–319.
   PubMed Web of Science ®Google Scholar
• DAMASCENO A, SANTOS A, SERRAO P et al.: Deficiency of renal dopaminergic-dependent natriuretic response to acute sodium load in black salt-sensitive subjects in contrast to salt-resistant subjects. Hypertens. (1999) 17:1995–2001.
   Web of Science ®Google Scholar
• NIELSEN CB, PEDERSEN EB: Abnormal distal tubular sodium reabsorption during dopamine infusion in patients with essential hypertension evaluated by the lithium clearance methods. Clin. Nephrol. (1997) 47: 304–309.
   PubMed Web of Science ®Google Scholar
• O'CONNELL DP, RAGSDALE V, BOYD DG, FELDER RA, CAREY PM: Differential human renal tubular responses to dopamine Type 1 receptor stimulation are determined by blood pressure status. Hypertension (1997) 29:115–122.
   PubMed Web of Science ®Google Scholar
• SANADA H, JOSE PA, HAZEN-MARTIND et al.: Dopamine-1 receptor couplingdefect in renal proximal tubule cells in hypertension. Hypertension (1999) 33:1036–1042.
   PubMed Web of Science ®Google Scholar
• •Important research into the defect in the dopamine pathway in human hypertension.
   Google Scholar
• KRUSHDAL J, XIONG M, FERRELL R: Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation. Hum. MoL Genet. (1998) 7:1379–1383.
   PubMed Web of Science ®Google Scholar
• LEE S-H, MINOWA MT, MOURADIAN MM: Two distinct promoters drive transcription of the human D1A dopamine receptor gene. J. Biol. Chem. (1996) 271:2529–9.
   Web of Science ®Google Scholar
• CICHRON H, NOTHEN MM, ERDMANN J, PROPPING P: Detection of four polymorphic sites in the human dopamine D1 receptor gene (DRD1). Hum. MoL Genet. (1994) 3:209.
   PubMed Web of Science ®Google Scholar
• SATO M, SOMA M, NAKAYAM T, KANMATSUSE K: Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension (2000) 36:183–186.
   PubMed Web of Science ®Google Scholar
• KUCHEL 0, SHIGETOMI S: Defective dopamine generation from dihydoxyphenylalanine in stable essential hypertensive patients. Hypertension (1992) 19:634–638.
   PubMed Web of Science ®Google Scholar
• LOKHANDWALA ME HUSSAIN T: Defective renal dopamine D1-like receptor signal transduction in obese hypertensive rats. Acta Physiol Scand. (2000) 168:251–255.
   PubMedGoogle Scholar
• SEGERS 0, GERLO E, DUPONT AG, SOMERS G: Decreased urinary dopamine excretion and disturbed dopamine/sodium relationship in Type I diabetes mellitus. Diabetes Med. (1995) 12:229–234.
   PubMed Web of Science ®Google Scholar
• SEGERS 0, ANCKAERT E, GERLO E, DUPONT AG, SOMERS G: Dopamine-sodium relationship in Type 2 diabetic patients. Diabetes Res. Clin. Pract. (1996) 34:89–98.
   PubMed Web of Science ®Google Scholar
• LUIPPOLD G, BEILHARZ M, MOHLBAUER B: Reduction of glomerular hyperfiltration by dopamine D2-like receptor blockade in experimental diabetes mellitus. Nephrol Dial. Transplant. (2001) 16:1350–1356.
   PubMed Web of Science ®Google Scholar
• FERREIRA A, BETTENCOURTP, PESTANA M et al.: Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. Clin. Sci. (Colchane) (2000) 99:195–200.
   PubMed Web of Science ®Google Scholar
• FERREIRA A, BETTENCOURT P, DIAS P et at Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin. Sci. (Lond) (2001) 100:557–566.
   PubMed Web of Science ®Google Scholar
• MACGREGOR DA, PRIELIPP RC, BLACK CS et al.: Renal dose dopamine does not alter the response to P-adrenergic stimulation by isoproterenol in healthy human volunteers. Chest (1997) 112: 40–44.
   PubMed Web of Science ®Google Scholar
• OLSEN NV, OLSEN MH, BONDE Jet al.:Dopamine natriuresis in salt-repleted, water-loaded humans: a dose-response study. Br. J. Clin. Pharmacol (1997) 43:509–520.
   Google Scholar
• SINDONE AP, KEOGH AM, MACDONALD PS, MCCOSKER CJ, KAAN AF: Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Jim. Heart. J. (1997) 134:889–900.
   PubMed Web of Science ®Google Scholar
• KELLUM JA, DECKER M: Use of dopamine in acute renal failure: a meta-analysis. Crit. Care Med. (2001) 29:1526–1531.
   PubMed Web of Science ®Google Scholar
• VARRIALE P, MOSSAVI A: The benefit oflow-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function? Clin. Cardiol (1997) 20:627–630.
   Web of Science ®Google Scholar
• BELLOMO R, CHAPMAN M, FINFER S, HICKLING K, MYBURGH J: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet (2000) 356:2139–2143.
   Google Scholar
• •Important trial of dopamine in renal dysfunction.
   Google Scholar
• PRINS I, PLOTZ FB, UITERWAAL CS, VAN VUGHT HT: Low-dose dopamine in neonatal and pediatric intensive care: a systematic review. Intensive Care Med. (2001) 27:206–210.
   PubMed Web of Science ®Google Scholar
• GARE M, HAVIV YS, BEN-YEHUDA A et al: The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography.j. Am. Coll. Cardiol (1999) 34: 1682-1688.
   Google Scholar
• HANS SS, HANS BA, DHILLON R, DMUCHOWSKI C, GLOVE J: Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am. Surg. (1998) 64:432–436.
   PubMed Web of Science ®Google Scholar
• SCHNUELLE P, LORENZ D, MUELLER A, TREDE M, VAN DER WOUDE FJ: Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney hat. (1999) 56:738–746.
   PubMed Web of Science ®Google Scholar
• FLANCBAUM L, DICK M, CHOBAN PS, DASTA JP: Effects of low-dose dopamine on urine output in oliguric, critically ill, renal transplant patients. Clin. Tranplant. (1998) 12:256–259.
   PubMed Web of Science ®Google Scholar
• SPICER ST, GRUENEWALD S, O'CONNELL PJ, CHAPMAN JR, NANKIVELL BJ: Low-dose dopamine after kidney transplantation: assessment by Doppler ultrasound. Gin. Transplant. (1999) 13:479–483.
   Web of Science ®Google Scholar
• GROSSMAN E, SHENKAR A, PELEG E,THALER M, GOLDSTEIN DS: Renal effects of L-DOPA in heart failure. J. Cardiovasc. Pharmacol (1999) 33:922–928.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA M, ENDO H, KOMATSU K et al.: Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-0,0-bis(ethoxycarbony0 dopamine (TS-870) in humans. Drug Metab. Dispos. (1990) 18:212–217.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA S, YAMAGUCHI I: A novel, orally active dopamine prodrug TA-870. V. Natriuretic and positive inotropic effects in rats: an assessment after chronic administration. J. Cardiovasc. Phapnacol. (1991) 17:768–777.
   Google Scholar
• SANADA H, ASICO LD, SHIGETOMI 5: The effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats. Gin. Exp. Hypertens. (2000) 22:419–429.
   PubMed Web of Science ®Google Scholar
• MATSUBAYASHI K, UEDA Y, OGINO H et al.: Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery. Thorac. Cardiovasc. Surg. (1999) 47: 352–356.
   PubMed Web of Science ®Google Scholar
• FUNASAK T, TSUTSUMIM TAKASE S et al.: Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. Am. J. Gastroenterol (1999) 94:2475–2481.
   Google Scholar
• EKLOF AC, HOLTBACK U, SUNDELOF M, CHEN S, APERIA A: Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na±,KLATPase. Kidney hat. (1997) 52:742–747.
   PubMed Web of Science ®Google Scholar
• WORTH DP, HARVEY JN, BROWN J, LEE MR: Patients with essential hypertension have an exaggerated natriuretic response to the dopamine pro-drug glutamyl-dopa. J. Hypertension. (1985) 3 (Suppl. 3):S179–S181.
   Google Scholar
• BARTHELMEBS M, VAILLY B, GRIMA M: Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin-induced diabetes in rats. J. Cardiovasc. Pbannacol (1991) 18:243–253.
   PubMed Web of Science ®Google Scholar
• DE TOLEDO FGS, THOMPSON MA, BOLLINGER C, TYCE GM, DOUSA TP: y-L-glutamyl-L-DOPA inhibits Nat-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate. Kidney Int. (1999) 55:1832–1842.
   PubMed Web of Science ®Google Scholar
• WAND Y, BERNDT TJ, GROSS JM et al.: Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin and on renal function. Am. J. Playsiol Regul Integr. Comp. Playsiol (2001) 280:R248–R254.
   PubMed Web of Science ®Google Scholar
• LAL MA, KORNER A, MATSUO Y et al: Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes (2000) 49:1381–1389.
   PubMed Web of Science ®Google Scholar
• VIEIRA-COELHO MA, GOMES P, SERRAO MP, SOARES-DA-SILVA P: Di-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors. Kidney mt. (2001) 59:1683–1694.
   PubMed Web of Science ®Google Scholar
• MIRAGOLI G, FERRINI R: Effect of ibopamine on diuresis in conscious rats in normal and experimentally altered conditions. Arzneimittelforstbung (1986) 36:318–322.
   PubMed Web of Science ®Google Scholar
• NICHOLS AJ, RUFFOLO RR Jr: Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine. Pbarmacol Exp. Met (1987) 242:455–465.
   PubMed Web of Science ®Google Scholar
• •Comprehensive description of the pharmacology of ibopamine at adrenoceptors.
   Google Scholar
• NICHOLS AJ, SMITH JM Jr, SHEBUSKI RUFFOLO RR Jr: Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog. J. Pbarmacol Exp. Met: (1987) 242:573–578.
   PubMed Web of Science ®Google Scholar
• STEFONI S, MOSCONI G, LA MANNA G et al.: Low-dosage ibopamine treatment in progressive renal failure: a long-term multicentre trial. Am. J. Neplarol. (1996) 16:489–499.
   Google Scholar
• LIE VERSE AG, GIRBES AR, VAN VELDHUISEN DJ: The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. Lim Heart J. (1995) 16:937–942.
   Web of Science ®Google Scholar
• VAN VELDHUISEN DJ, BROUWER J, MAN IN 'T VELD et al.: Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial. Am. J. Cardiol (1995) 75:796–800.
   Google Scholar
• ANDREWS R, CHARLESWORTH A, EVANS A, COWLEY Al: A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Lim Heart J. (1997) 18:852–857.
   Web of Science ®Google Scholar
• DOHMEN HJ, DUNSELMAN PH, POOLE-WILSON PA: Comparison of captopril and ibopamine in mild to moderate heart failure. Heart (1997) 78:285–290.
   PubMed Web of Science ®Google Scholar
• SZABO BM, VAN VELDHUISEN DJ, VAN DER BURGH PH, KRUIK J, GIRBES AR, LIE KI: Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. J. Card Fail. (1996) 2:185–192.
   PubMedGoogle Scholar
• METRA M, DEI CAS L: Clinical efficacy of ibopamine in patients with chronic heart failure. Clin. Cardiol (1995) 18(Suppl. I):I22–131.
   Google Scholar
• HAMPTON JR, VAN VELDHUISEN DJ, KLEBER FX et al.: Randomised study of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet (1997) 349:971–977.
   Google Scholar
• •Study demonstrating increased mortality with ibopamine in heart failure.
   Google Scholar
• FEENSTRA J, IN'T VELD BA, VAN DER LINDEN PD, GROBBE DE, STRICKER BH: Risk factors for mortality in users of ibopamine. Br..! Clin. Pbarmacol (1998) 46:71–77.
   PubMed Web of Science ®Google Scholar
• TEISMAN AC, BUIKEMA H, VAN VELDHUISEN DJ, DE ZEEUW D, VAN GILST WH: Direct vasodilating effects of the new dopaminergic agonist Z-1046 in human arteries. J. Cardiovasc. Pbarmacol (2000) 35:581–585.
   PubMed Web of Science ®Google Scholar
• DUNCKER DJ, HAITSMA DB, VAN DER GEEST IEJ et al.: Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z-1046. Br. J. Pharmacol (1997) 120:1101–1113.
   Google Scholar
• HALPENNY M, LAKSHMI S, O'DONNELL A, O'CALLAGHAN-ENRIGHT S, SHORTEN GD: Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia (2001) 56:953–960.
   PubMed Web of Science ®Google Scholar
• TUMLIN JA, DUNBAR LM, OPARIL S et al.: Fenoldopam, a dopamine agonist for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad. Emerg. Med. (2000) 7:653–662.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, LASS NA, GLOCK D: Renalhemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney [nt. (1999) 56:206–210.
   PubMed Web of Science ®Google Scholar
• SCHWIEGER IM, SCHIFFER ER, MOREL DR: Effects of fenoldopam on systemic and splanchnic haemodynamics and oxygen delivery/consumption relationship during hyperdynamic ovine endotoxaemia. Intensive Care Med. (1998) 24:509–518.
   PubMed Web of Science ®Google Scholar
• BROOKS DP, DEPALMA PD, CYRONAK MJ et al.: Identification of fenoldopam prodrugs with prolonged vasodilator activity. J. Pbarmacol Exp. Titer. (1990) 254:1084–1089.
   PubMed Web of Science ®Google Scholar
• BROOKS DP, MITCHELL MP, SHORT BG, RUFFOLO RR Jr, NICHOLS Al. Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058. j Pbarmacol Exp. Titer. (1991) 257:1243–1247.
   Google Scholar
• YATSU T, TAKIZAWA K, KASAI-NAKAGAWA C et al: Hemodynamic characterization of YM-435, a novel dopamine DAi-receptor agonist, in anaesthetized dogs. Cardiovasc. Pbarmacol (1997) 29:382–388.
   PubMed Web of Science ®Google Scholar
• YATSU T, ARAI Y, TAKIZAWA K et al: Effect of YM-435, a dopamine DAi receptor agonist, in a canine model of ischemic acute renal failure. Gen. Pbarmacol (1998) 31:803–807.
   PubMed Web of Science ®Google Scholar
• VAN VELDHUISEN DJ, GIRBES AR, DE GRAEFF PA, LIE KI: Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure. hat. J Cardiol (1992) 37:293–300.
   Web of Science ®Google Scholar
• THE XAMOTEROL IN SEVERE HEART FAILURE STUDY GROUP: Xamoterol in severe heart failure. Lancet (1990) 336:1–6.
   PubMed Web of Science ®Google Scholar
• O'CONNOR CM, GATTIS WA, URETSKY BF et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart" (1999) 138:78–86.
   Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• COWLEY AJ, SKENE AM: Treatment of severe heart failure: quantity or quality of life? A trial of encodmone. Enoximone Investigators. Br. Heart J. (1994) 72:226–230.
   PubMed Web of Science ®Google Scholar